Volume 17, Number 6—June 2011
Dispatch
Salmonella enterica Serotype Typhi with Nonclassical Quinolone Resistance Phenotype
Table 2
Characteristics of the 11 Salmonella enterica serovar Typhi isolates belonging to subpopulation B, France, 2007–2009
Isolate | Year | Geographic origin | Antimicrobial drug resistance type | Disk diffusion, mm |
MIC, μg/mL |
gyrB | Haplotype | PFGE | |||
---|---|---|---|---|---|---|---|---|---|---|---|
Nal | Cip | Nal | Cip | ||||||||
97-5123 | 1997 | Unknown | CipDS | 18 [I] | 28 [S] | 8 [S/S] | 0.125 [S/S] | Tyr464 | Non-H58 | X8 | |
02-2759 | 2002 | India | CipDS | 19 [I] | 26 [S] | 4 [S/S] | 0.125 [S/S] | Phe464 | H58 | X2 | |
05-1578 | 2005 | India | Pansusceptible | 18 [I] | 28 [S] | 8 [S/S] | 0.047 [S/S] | Asp466 | Non-H58 | X6 | |
05-2556 | 2005 | India | CipDS | 17 [I] | 31 [S] | 16 [I/S] | 0.19 [S/S] | Phe464 | Non-H58 | X7 | |
05-9141 | 2005 | India | CipDS | 17 [I] | 28 [S] | 12 [I/S] | 0.125 [S/S] | Tyr464 | Non-H58 | X3 | |
06-426 | 2006 | India | CipDS | 20 [S] | 25 [S] | 8 [S/S] | 0.125 [S/S] | Tyr464 | Non-H58 | X3 | |
07-6086 | 2007 | Tunisia | Pansusceptible | 16 [I] | 31 [S] | 16 [I/S] | 0.047 [S/S] | WT | ND | ND | |
08-7675† | 2008 | India | ASCSulTmpSXTCipDS | 18 [I] | 28 [S] | 8 [S/S] | 0.125 [S/S] | Phe464 | H58 | X1 | |
09-1986† | 2008 | India | ASCSulTmpSXTCipDS | 18 [I] | 27 [S] | 8 [S/S] | 0.125 [S/S] | Phe464 | ND | X1 | |
09-0350 | 2009 | Unknown | CipDS | 19 [I] | 27 [S] | 8 [S/S] | 0.125 [S/S] | Phe464 | Non-H58 | X5 | |
09-2317 | 2009 | French Guyana | Pansusceptible | 19 [I] | 32 [S] | 8 [S/S] | 0.032 [S/S] | Glu468 | Non-H58 | X4 |
*PFGE, pulsed-field gel electrophoresis; Nal, nalidixic acid; Cip, ciprofloxacin; WT, wild type; ND, not determined; A, ampicillin; S, streptomycin, C, chloramphenicol; Su, sulfamethoxazole; Tmp, trimethoprim; SXT, cotrimoxazole; CipDS, decreased susceptibility to ciprofloxacin. Disk diffusion test was performed and interpreted ([S], susceptible; [I], intermediate) following recommendations of antibiogram committee of the French Society for Microbiology. MICs were determined by Etest strips, and categorization was made according to the French Society for Microbiology and Clinical and Laboratory Standards Institute.
†Previously described same patient (13).
References
- Crump JA, Mintz ED. Global trends in typhoid and paratyphoid fever. Clin Infect Dis. 2010;50:241–6. DOIPubMedGoogle Scholar
- Wain J, Kidgell C. The emergence of multidrug resistance to antimicrobial agents for the treatment of typhoid fever. Trans R Soc Trop Med Hyg. 2004;98:423–30. DOIPubMedGoogle Scholar
- Wain J, Hoa NT, Chinh NR, Vinh H, Everett MJ, Diep TS, Quinolone-resistant Salmonella typhi in Vietnam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis. 1997;25:1404–10. DOIPubMedGoogle Scholar
- Roumagnac P, Weill FX, Dolecek C, Baker S, Brisse S, Chinh NT, Evolutionary history of Salmonella Typhi. Science. 2006;314:1301–4. DOIPubMedGoogle Scholar
- Le TA, Fabre L, Roumagnac P, Grimont PA, Scavizzi MR, Weill FX. Clonal expansion and microevolution of quinolone-resistant Salmonella enterica serotype Typhi in Vietnam from 1996 to 2004. J Clin Microbiol. 2007;45:3485–92. DOIPubMedGoogle Scholar
- Aarestrup FM, Wiuff C, Mølbak K, Threlfall EJ. Is it time to change fluoroquinolone breakpoints for Salmonella spp.? Antimicrob Agents Chemother. 2003;47:827–9. DOIPubMedGoogle Scholar
- Crump JA, Kretsinger K, Gay K, Hoekstra RM, Vugia DJ, Hurd S, Clinical response and outcome of infection with Salmonella enterica serotype Typhi with decreased susceptibility to fluoroquinolones: a United States FoodNet Multicenter Retrospective Cohort Study. Antimicrob Agents Chemother. 2008;52:1278–84. DOIPubMedGoogle Scholar
- Crump JA, Barrett TJ, Nelson JT, Angulo FJ. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae. Clin Infect Dis. 2003;37:75–81. DOIPubMedGoogle Scholar
- Booker BM, Smith PF, Forrest A, Bullock J, Kelchlin P, Bhavnani SM, Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype Typhi. Antimicrob Agents Chemother. 2005;49:1775–81. DOIPubMedGoogle Scholar
- Cooke FJ, Day M, Wain J, Ward LR, Threlfall EJ. Cases of typhoid fever imported to England, Scotland and Wales (2000–2003). Trans R Soc Trop Med Hyg. 2007;101:398–404. DOIPubMedGoogle Scholar
- Lynch MF, Blanton EM, Bulens S, Polyak C, Vojdani J, Stevenson J, Typhoid fever in the United States, 1999–2006. JAMA. 2009;302:859–65. DOIPubMedGoogle Scholar
- Song Y, Roumagnac P, Weill FX, Wain J, Dolecek C, Mazzoni CJ, A multiplex single nucleotide polymorphism typing assay for detecting mutations that result in decreased fluoroquinolone susceptibility in Salmonella enterica serovars Typhi and Paratyphi A. J Antimicrob Chemother. 2010 Jun 1. PMID: 20511368
- Gaborieau V, Weill FX, Marchou B. Salmonella enterica serovar Typhi with decreased susceptibility to ciprofloxacin: a case report [in French]. Med Mal Infect. 2010;40:691–5. DOIPubMedGoogle Scholar
- Sjölund-Karlsson M, Howie R, Rickert R, Krueger A, Tran TT, Zhao S, Plasmid-mediated quinolone resistance among non-Typhi Salmonella enterica isolates, USA. Emerg Infect Dis. 2010;16:1789–91.PubMedGoogle Scholar